Anthos Therapeutics
Anthos Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardiovascular metabolic diseases, with a focus on a novel anticoagulant therapy addressing unmet needs. Their mission is to redefine cardiovascular care through pioneering therapies that inspire hope and healing, aiming to improve the lives of patients worldwide.
Industries
Nr. of Employees
small (1-50)
Anthos Therapeutics
Cambridge, Massachusetts, United States, North America
Products
Investigational Factor XI inhibitor (fully human monoclonal antibody; investigational anticoagulant)
A fully human monoclonal antibody therapeutic developed to inhibit Factor XI/XIa with long-acting pharmacology intended for prevention and treatment of arterial and venous thromboembolism; administered subcutaneously once monthly in pivotal regimens.
Investigational Factor XI inhibitor (fully human monoclonal antibody; investigational anticoagulant)
A fully human monoclonal antibody therapeutic developed to inhibit Factor XI/XIa with long-acting pharmacology intended for prevention and treatment of arterial and venous thromboembolism; administered subcutaneously once monthly in pivotal regimens.
Services
Clinical development of investigational biologics
Design and conduct of Phase 2 and Phase 3 clinical studies for investigational biologic therapies targeting thrombotic diseases, including trial governance and global site management.
Medical education and professional engagement
Provision and sponsorship of educational activities for healthcare professionals and partnerships with patient advocacy organizations to disseminate scientific information and accredited learning.
Clinical development of investigational biologics
Design and conduct of Phase 2 and Phase 3 clinical studies for investigational biologic therapies targeting thrombotic diseases, including trial governance and global site management.
Medical education and professional engagement
Provision and sponsorship of educational activities for healthcare professionals and partnerships with patient advocacy organizations to disseminate scientific information and accredited learning.
Expertise Areas
- Clinical trial management (Phase 2–3)
- Anticoagulant therapeutics development
- Monoclonal antibody biologics
- Regulatory strategy and expedited pathways
Key Technologies
- Factor XI / FXIa inhibition therapeutics
- Fully human monoclonal antibody therapeutics
- Long-acting subcutaneous biologic dosing
- PK/PD and biomarker assays for target engagement